The Potential Expansion of Ireland’s Seasonal Influenza Vaccination Programme: An Evaluation

By Staff Writer

August 23, 2023

Seasonal influenza, a contagious respiratory illness, is a global health concern that can lead to serious complications, especially among vulnerable groups. The World Health Organization estimates that this disease accounts for approximately 290,000 to 650,000 respiratory deaths annually worldwide. In Ireland, the Health Service Executive’s Seasonal Influenza Vaccination Programme offers a free annual influenza vaccine to certain population groups, including adults aged 65 years or older, healthcare workers, those with certain medical conditions, pregnant women, and carers.

Recently, the Health Information and Quality Authority (HIQA) conducted a rapid health technology assessment (HTA) to evaluate whether the vaccination programme should be temporarily expanded for the 2023-2024 season to include individuals aged 50 to 64 years. This follows a similar temporary measure implemented for the 2021-2022 season due to the widespread circulation of SARS-CoV-2.


The rapid HTA, carried out by an Evaluation Team from the HTA Directorate at HIQA, revealed that the vaccine uptake has averaged 28% in those aged 50 to 64 years over the last two influenza seasons. The team found that extending eligibility could result in a modest increase in uptake, provided it is supported by a public health information campaign. The estimated cost of this extension for the 2023-2024 influenza season is approximately €2.3 million, assuming that total uptake in this age group increases from 28% to 35%.


However, the team also noted substantial uncertainty regarding the potential costs and benefits of expanding reimbursement to this age group. Given the relatively modest number of influenza-related hospitalisations in this age group and the substantial year-on-year variability in vaccine effectiveness, the potential for a reduction in demand for hospital care is likely to be small.

Based on these findings, HIQA advises the Minister for Health and the Department of Health to consider limiting the programme extension due to an apparent trend of increasing burden with increased age. If the programme were to be extended just to those aged 60 years and older, the estimated incremental cost for 2023-2024 would be €0.68 million. If extended to those aged 55 years and older, the cost would be €1.43 million.

Should the decision be made to expand the HSE Seasonal Influenza Vaccination Programme, HIQA recommends enhanced data collection and public health information campaigns to empower individuals and support informed decision-making.

Reference url

Recent Posts

prior authorization reforms
     

Streamlining Prior Authorization Reforms: Impacts and Insights for HEOR

🚀 Are prior authorizations stalling care delivery in the U.S. healthcare system?

The HHS has launched an ambitious collaboration with major insurers to reform prior authorization processes across Medicare Advantage, Medicaid, and commercial plans. With a goal to standardize submissions by 2027 and significantly reduce requirements by 2026, this initiative promises to accelerate care decisions and enhance transparency.

Dive into the details of these pivotal reforms and discover their potential to streamline healthcare and improve patient outcomes.

#SyenzaNews #HealthcareInnovation #healthcare #healthcarepolicy

private health funding
    

Private Health Funding Under South Africa’s National Health Insurance Act

🚀 Update on NHI in South Africa.

In their insightful article, Solanki et al. discuss the complexities of private health funding amidst the nation’s National Health Insurance Act. They discuss two key scenarios: a passive approach that risks the sustainability of the private sector and an active reform strategy that could ensure a smoother transition to universal coverage.

Curious about how these strategies could reshape healthcare access and costs in South Africa? Don’t miss out on this critical analysis!

#SyenzaNews #HealthEconomics #HealthcarePolicy

drug price transparency
     

Impending Net Drug Price Transparency Regulation in the U.S.

💡 Are you ready for a potential game-changer in drug pricing transparency?

CMS Administrator Mehmet Oz has hinted at a new rule aimed at enforcing stricter disclosures for drug prices, requiring healthcare companies to reveal actual transaction costs. This could reshape how price transparency is managed across the industry and challenge pharmacy benefit managers to rethink rebate practices.

Curious about how this will impact healthcare economics and what it means for drug affordability? Dive into the article for all the insights!

#SyenzaNews #healthcare #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.